Bio-interventional uveoscleral outflow augmentation using a scleral allograft is a promising and well-tolerated approach for reducing intraocular pressure (IOP) and medication dependence in patients with medically uncontrolled glaucoma undergoing cataract surgery, according to a study presented at AGS 2025.
The study included 51 eyes with a baseline medicated IOP of 25.7 ± 4.4 mmHg. The bio-tissue implant demonstrated excellent biocompatibility, stability, and conformance to native ocular structures, with no signs of persistent inflammation or migration. At 12 months, there was a 39.7% reduction in mean medicated IOP (P < 0.001) and a 41.1% decrease in the use of IOP-lowering medications (P < 0.01).
The researchers concluded that intraocular implantation of a scleral allograft for bio-scaffolding and reinforcement of the uveoscleral outflow pathway is highly biocompatible and well-tolerated.
Reference
Weinreb R, et al. Bio-tissue Uveroscleral Reinforcement in Patients Undergoing Cataract Surgery and Failing IOP Control with Topical Medication Therapy. Poster presented at: American Glaucoma Society Annual Meeting; February 26–March 2, 2025; Washington, DC.
Related Content
